Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inspection Fees For Drug, Ingredient Manufacturers Could End Up In PDUFA, Sen. Harkin Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The chairman of the HELP committee also open to a track and trace mechanism for drugs and their ingredients and denying U.S. entry to drugs from facilities that deny entry to U.S. inspectors.

You may also be interested in...



Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed

At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.

Supply Chain Security Issues To Emerge During Subcommittee Hearing On PDUFA

USP To Bring Global Perspective To Track And Trace Discussion

The U.S. Pharmacopeial Convention released a framework Jan. 4 for instituting supply chain security measures and plans a May workshop with speakers from other countries to discuss their programs for tracking drug components and products through distribution channels.

Related Content

Topics

UsernamePublicRestriction

Register

PS072767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel